Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$100.00 -1.9%	$109.66	$81.20 ▼ $131.49	$24.04B	1.39	759,110 shs	505,409 shs
RVMD Revolution Medicines	$37.97 -0.9%	$37.26	$29.17 ▼ $62.40	$7.10B	1.12	2.06 million shs	1.94 million shs
SMMT Summit Therapeutics	$23.70 -2.9%	$25.53	$11.76 ▼ $36.91	$17.61B	-1.02	3.22 million shs	2.54 million shs
TEVA Teva Pharmaceutical Industries	$18.41 +2.0%	$16.86	$12.47 ▼ $22.80	$21.08B	0.72	10.85 million shs	7.15 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	-9.81%	-6.98%	+4.48%	+13.38%
RVMD Revolution Medicines	0.00%	+2.59%	+1.88%	-5.03%	-10.97%
SMMT Summit Therapeutics	0.00%	-9.54%	-10.13%	+27.01%	+80.64%
TEVA Teva Pharmaceutical Industries	0.00%	-0.32%	+19.09%	+9.76%	-0.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.8279 of 5 stars	4.4	2.0	0.0	3.5	0.8	0.0
RVMD Revolution Medicines	4.3496 of 5 stars	4.5	1.0	4.7	3.7	1.7	0.0
SMMT Summit Therapeutics	2.6959 of 5 stars	4.3	1.0	0.0	3.5	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.1018 of 5 stars	3.6	4.0	0.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.76	Moderate Buy	$135.80	35.80% Upside
RVMD Revolution Medicines	3.00	Buy	$69.92	84.15% Upside
SMMT Summit Therapeutics	2.63	Moderate Buy	$33.31	40.54% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	34.27% Upside

Current Analyst Ratings Breakdown

Latest RVMD, BNTX, TEVA, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$44.00 ➝ $50.00
8/19/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$21.00
8/19/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
8/18/2025	RVMD Revolution Medicines	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$75.00
8/18/2025	SMMT Summit Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$21.00
8/18/2025	RVMD Revolution Medicines	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$80.00
8/15/2025	RVMD Revolution Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$67.00
8/15/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
8/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$138.00 ➝ $136.00
8/14/2025	SMMT Summit Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $34.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.07	N/A	N/A	$87.61 per share	1.14
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	$13.47 per share	N/A
SMMT Summit Therapeutics	$700K	25,150.78	N/A	N/A	$0.53 per share	44.72
TEVA Teva Pharmaceutical Industries	$16.54B	1.28	$3.37 per share	5.46	$4.74 per share	3.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$1.60	N/A	N/A	N/A	-12.20%	-1.84%	-1.59%	11/3/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.50	N/A	N/A	N/A	N/A	-41.78%	-35.63%	11/5/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$1.01	N/A	N/A	N/A	N/A	-208.64%	-181.28%	10/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	7.00	1.09	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest RVMD, BNTX, TEVA, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	-$0.76	-$0.66	-$0.76	N/A	N/A
8/6/2025	Q2 2025	RVMD Revolution Medicines	-$0.94	-$1.31	-$0.37	-$1.31	$0.50 million	N/A
8/4/2025	Q2 2025	BNTX BioNTech	-$1.41	-$1.60	-$0.19	-$1.82	$161.26 million	$306.46 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.61	8.48
RVMD Revolution Medicines	0.13	11.79	11.79
SMMT Summit Therapeutics	N/A	5.13	5.13
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
RVMD Revolution Medicines	94.34%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
RVMD Revolution Medicines	8.20%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.40 million	194.24 million	Optionable
RVMD Revolution Medicines	250	186.93 million	171.60 million	Optionable
SMMT Summit Therapeutics	110	742.85 million	112.17 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

RVMD, BNTX, TEVA, and SMMT Headlines

Recent News About These Companies

Iron Triangle Partners LP Has $34.09 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

August 31 at 6:40 AM | marketbeat.com

Gabelli Funds LLC Boosts Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 31 at 5:22 AM | marketbeat.com

Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda

August 31 at 2:47 AM | finance.yahoo.com

Tri Locum Partners LP Sells 1,362,108 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 30 at 8:04 AM | marketbeat.com

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

August 29 at 3:15 PM | pharmaceutical-technology.comP

USFDA approves Teva Pharma generic Saxenda for weight loss

August 29 at 9:54 AM | medicaldialogues.inM

Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY

August 29 at 9:54 AM | finance.yahoo.com

APG Asset Management N.V. Decreases Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 29 at 5:06 AM | marketbeat.com

Analysts Set Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Target Price at $24.71

August 29 at 2:35 AM | americanbankingnews.com

Teva stock rises on launch of first generic weight loss GLP-1 drug

August 28 at 11:10 AM | in.investing.com

TEVA Trumpets Saxenda, Stocks Eke Higher

August 28 at 11:10 AM | baystreet.ca

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

August 28 at 11:10 AM | finance.yahoo.com

US FDA approves Teva Pharmaceuticals' generic obesity drug

August 28 at 9:17 AM | reuters.com

Raymond James Financial Inc. Decreases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

August 28 at 4:00 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Recommendation of "Buy" from Analysts

August 28 at 3:26 AM | marketbeat.com

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

August 28 at 2:01 AM | seekingalpha.com

How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy

August 27, 2025 | finance.yahoo.com

Quantbot Technologies LP Has $703,000 Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

August 27, 2025 | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Has $653,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 26, 2025 | marketbeat.com

Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

August 25, 2025 | insidermonkey.com

Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

August 25, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD, BNTX, TEVA, and SMMT Company Descriptions

BioNTech NASDAQ:BNTX

$100.00 -1.93 (-1.89%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$100.00 0.00 (0.00%)

As of 08/29/2025 07:57 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Revolution Medicines NASDAQ:RVMD

$37.97 -0.36 (-0.94%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$37.53 -0.44 (-1.17%)

As of 08/29/2025 07:57 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Summit Therapeutics NASDAQ:SMMT

$23.70 -0.72 (-2.95%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$23.81 +0.11 (+0.46%)

As of 08/29/2025 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$18.41 +0.37 (+2.03%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$18.40 -0.01 (-0.06%)

As of 08/29/2025 07:56 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time